ATRS NASDAQ
Antares Pharma, Inc.
1W: +0.4%
1M: +0.4%
3M: +62.0%
1Y: +37.0%
3Y: +96.8%
5Y: +128.2%
$5.59
Last traded 2022-05-23 — delisted
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
5 relationships0
As Filer
counterparties named
5
As Counterparty
mentioned by others
2021-10-18
Earliest Filing
2022-05-24
Latest Filing
Mentioned As Counterparty
5 mentionsOther companies that named ATRS in their SEC 8-K filings.
| Filed By | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|
| HALO HALOZYME THERAPEUTICS, INC. | acquirer | Target company acquired via tender offer and merger by Atlas Merger Sub, Inc. | 2022-05-24 | View |
| HALO HALOZYME THERAPEUTICS, INC. | acquirer | Target company in a cash tender offer and merger agreement with Halozyme Therapeutics, Inc. | 2022-04-13 | View |
| LPCN Lipocine Inc. | partner | Lipocine Inc. amended an exclusive license agreement for TLANDO product rights in the US, extending the option deadline | 2022-04-01 | View |
| ASRT Assertio Holdings, Inc. | target | Assertio Holdings acquired Otrexup rights and assets from Antares Pharma in a $44 million transaction. | 2021-12-16 | View |
| LPCN Lipocine Inc. | partner | Exclusive U.S. licensing partner for TLANDO commercialization | 2021-10-18 | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR